You have read all your free articles, to continue reading subscribe to read the rest of this content.
Biovica has acquired cSens, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness. The cSens technology complements Biovica’s current TK assay DiviTum ™, which is curAlready a subscriber Login You have read all…
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). “Already a subscriber Login You have read all your free articles, to continue reading subscribe to…
AstraZeneca has made a preliminary approach to Gilead Sciences about a potential merger, according to Bloomberg. AstraZeneca informally contacted Gilead last month to gauge its interest in a possible tie-up asking not to be identified because the details are private, reports Bloomberg. AstraZenecAlready a subscriber Login You have read all…
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca emAlready a subscriber Login You have read…
